AR and posterior cortical atrophy: At the molecular level, androgen receptor-positive PCa and advanced diseases with mutations in DNA damage response genes (e.g., BRCA1/2) are eligible for systemic anti-androgen therapy to block the activation of androgen receptors and for treatment with poly (ADP-ribose) polymerase inhibitors (PARPi), respectively (6).